검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AP1903 |
Overview Company | Beijing Biotech |
Overview Modality | CGT |
Overview Target | Sarcoma |
Overview Indication | Leukemia; Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting the AML-associated antigen |
MoA Biomarker | CD19 and iCaspase-9 expression |
PK/PD Species | Mouse, In in vitro and in vivo models |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, In in vitro and in vivo models |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03056339 |
Clinical Data Tier / Score | A · 33 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AP1903 |
Overview Company | Beijing Biotech |
Overview Modality | CGT |
Overview Target | Sarcoma |
Overview Indication | Leukemia; Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting the AML-associated antigen |
MoA Biomarker | CD19 and iCaspase-9 expression |
PK/PD Species | Mouse, In in vitro and in vivo models |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, In in vitro and in vivo models |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03056339 |
Clinical Data Tier / Score | A · 33 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교